Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Plataforma de servicios de apoyo para procesos de calidad por diseño en el marco de desarrollo de nanofármacos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20161024001
Publicado:
11/11/2016
Caducidad:
11/11/2017
Resumen:
Una start-up francesa con experiencia en desarrollo de nanofármacos ha desarrollado una plataforma segura basada en web para orientar automáticamente a personas no expertas a través del flujo de trabajo de calidad por diseño, también asistido por un bioestadístico para análisis de riesgos, diseño de experimentos y control de procesos. El principal objetivo es identificar, analizar y controlar todas las causas de las variaciones que pueden alterar finalmente la calidad y seguridad del medicamento. Para lograr dicho fin, este enfoque se basa en varios métodos estadísticos y herramientas de análisis previo de riesgos, diseño de experimentos, análisis de múltiples variables y control estadístico de procesos. La empresa busca desarrolladores de nanofármacos interesados en utilizar la plataforma en sus proyectos, ofreciéndose a mejorar la solución. El objetivo es establecer acuerdos de servicio o cooperación técnica.

Details

Tittle:
Support services platform for "Quality by design" process in the frame of nano-drugs development
Summary:
A French Start-up, with expertise in Nano-drugs development, has developed a secured web-based platform that automatically guides non-experts through the "Quality by Design" workflow, also assisted by a biostatistician for the risk analysis, design of experiments and process controls. Service agreement or technical cooperation agreement is sought with developers of Nano-drugs who could use the platform for their own projects, where the company could enhance the solution.
Description:
A nano-drug consists of two things: an active principle (molecule that will cure the diseased area) and a vehicle (scientific term: vector) of nanometric size. The vehicle of the nano-drug is able to transport the molecule to the infected zone - a gene, a protein, a cell, an organ - and to treat directly the infected cells without damaging the healthy cells around. Nano-drugs are promising prospects for treating severe diseases such as cancer, diabetes, Alzheimer´s, multiple sclerosis.
But development of nano-drugs generally requests a large number of experimentations to find the good molecule configuration and good process parameters, ensuring safety for the patient.

A French Start-up has developed the first collaborative platform designed to broaden the use of Quality-by-Design for Nano-drugs development.
Pharmaceutical Quality-by-Design is a risk-based approach of drug development based on the understanding of both the product and the process. Its main objective is to identify, analyze and control all causes of variations that could finally alter quality and safety of the drug. To that aim, this approach employs several statistical methods and tools such as prior risk analysis, design of experiments, multivariate analysis and statistical process control. Quality by Design is now strongly recommended by U.S. Food and Drug Administration and European Medicines Agency in all drug development projects.

Innovating for over 10 years in the development of rational methods of design and production of new molecules, the company has developed strong expertise in statistical design of experiences.
The Quality by Design platform is a collaborative service for physicists, biologists and chemists who wish to be assisted in the development of their molecules and nanoparticles in compliance with the Food and Drug Administration and European Medicines Agency guidelines related to Quality-by-Design.

The interactive internet platform guides them in each stage of their preclinical developments through an ergonomic and easy to use interface.
During the development phases, the client is assisted by a biostatistician for the risk analysis, design of experiments and process controls, who is involved in every step of Quality by Design process.
Thanks to the service, from several millions of possible formulations, the user will identify less than 100 prototypes, drastically reducing the number of experiments needed.

Advantages and Innovations:
Thanks to the platform and support services, Nano-drugs developers will be able to :
- demonstrate to the FDA -Y- EMA both the product´s knowledge and its process of manufacturing.
- improve the quality and control safety by risks analysis of their product,
- significantly reduce the risks of non-compliance
- drastically reduce the number of necessary experimentations
- saving time and money in preclinical development
- with the collaborative platform, users spread over several European countries can work remotely
Stage of Development:
Already on the market
IPs:
Copyright

Partner sought

Type and Role of Partner Sought:
Services agreement is sought with developpers of nano-drugs who would be interested in using the platform and services in the frame of their own drugs development.
Technical cooperation agreement is also sought in the frame of collaborative projects where the company could enhance the platform and services features and performance.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002001 Bioquímica / biofísica
06001003 Citología, cancerología, oncología
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06006006 Nanomateriales biológicos
06001015 Productos farmacéuticos / medicamentos